Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Vulvovaginal Candidiasis Treatment Market, by Distribution Channel
1.4.2 Europe Vulvovaginal Candidiasis Treatment Market, by Route of Administration
1.4.3 Europe Vulvovaginal Candidiasis Treatment Market, by Drug Class
1.4.4 Europe Vulvovaginal Candidiasis Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Vulvovaginal Candidiasis Treatment Market by Distribution Channel
3.1 Europe Retail Pharmacy Market by Country
3.2 Europe Hospital Pharmacy Market by Country
3.3 Europe Online Pharmacy Market by Country
Chapter 4. Europe Vulvovaginal Candidiasis Treatment Market by Route of Administration
4.1 Europe Oral Market by Country
4.2 Europe Intravenous Market by Country
4.3 Europe Topical Market by Country
Chapter 5. Europe Vulvovaginal Candidiasis Treatment Market by Drug Class
5.1 Europe Fluconazole Market by Country
5.2 Europe Clotrimazole Market by Country
5.3 Europe Terconazole Market by Country
5.4 Europe Terbinafine Market by Country
5.5 Europe Nystatin Market by Country
5.6 Europe Ketoconazole Market by Country
5.7 Europe Others Market by Country
Chapter 6. Europe Vulvovaginal Candidiasis Treatment Market by Country
6.1 Germany Vulvovaginal Candidiasis Treatment Market
6.1.1 Germany Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.1.2 Germany Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.1.3 Germany Vulvovaginal Candidiasis Treatment Market by Drug Class
6.2 UK Vulvovaginal Candidiasis Treatment Market
6.2.1 UK Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.2.2 UK Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.2.3 UK Vulvovaginal Candidiasis Treatment Market by Drug Class
6.3 France Vulvovaginal Candidiasis Treatment Market
6.3.1 France Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.3.2 France Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.3.3 France Vulvovaginal Candidiasis Treatment Market by Drug Class
6.4 Russia Vulvovaginal Candidiasis Treatment Market
6.4.1 Russia Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.4.2 Russia Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.4.3 Russia Vulvovaginal Candidiasis Treatment Market by Drug Class
6.5 Spain Vulvovaginal Candidiasis Treatment Market
6.5.1 Spain Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.5.2 Spain Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.5.3 Spain Vulvovaginal Candidiasis Treatment Market by Drug Class
6.6 Italy Vulvovaginal Candidiasis Treatment Market
6.6.1 Italy Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.6.2 Italy Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.6.3 Italy Vulvovaginal Candidiasis Treatment Market by Drug Class
6.7 Rest of Europe Vulvovaginal Candidiasis Treatment Market
6.7.1 Rest of Europe Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.7.2 Rest of Europe Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.7.3 Rest of Europe Vulvovaginal Candidiasis Treatment Market by Drug Class
Chapter 7. Company Profiles
7.1 Bayer AG
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Pfizer, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional & Segmental Analysis
7.2.4 Research & Development Expense
7.3 Bristol Myers Squibb Company
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.4 Astellas Pharma, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expense
7.5 Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management, LLC)
7.5.1 Company Overview
7.5.2 Recent strategies and developments:
7.5.2.1 Trials and Approvals:
7.6 Basilea Pharmaceutica Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expenses
7.7 Scynexis, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expenses
7.7.4 Recent strategies and developments:
7.7.4.1 Trials and Approvals:
7.8 Grupo Ferrer Internacional S.A.
7.8.1 Company Overview
Unique Offerings 